Aclaris Therapeutics (ACRS) Share-based Compensation (2014 - 2026)

Aclaris Therapeutics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 9.53% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $12.0 million (down 2.07% YoY), while the FY2025 annual figure was $12.4 million, up 14.08% from the prior year.
• Share-based Compensation was $3.2 million for Q1 2026 at Aclaris Therapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.8 million in Q1 2023 to a low of $1.3 million in Q4 2023.
• Historically, Share-based Compensation has averaged $3.6 million across 5 years, with a median of $3.1 million in 2025.
• Biggest YoY gain for Share-based Compensation was 190.11% in 2023; the steepest drop was 73.7% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $4.8 million in 2022, then slumped by 73.7% to $1.3 million in 2023, then jumped by 125.91% to $2.9 million in 2024, then gained by 2.31% to $2.9 million in 2025, then increased by 9.3% to $3.2 million in 2026.
• The last three Share-based Compensation figures came in at $3.2 million (Q1 2026), $2.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.